Interstitial fibrosis is the buildup of scar tissue in the spaces between the functional cells of an organ. It can affect the lungs, kidneys, heart, and liver, and in each case the scarring gradually replaces healthy tissue, making the organ stiffer and less able to do its job. The most commonly discussed form is pulmonary (lung) fibrosis, but the underlying process is similar regardless of where it occurs.
How Scarring Develops
Every organ has a structural framework, a kind of scaffolding that holds its working cells in place. This framework is called the interstitium, and it’s made up of connective tissue proteins like collagen. Under normal circumstances, when tissue is injured, specialized repair cells called myofibroblasts activate, lay down new collagen, and then quiet down once the wound heals. In interstitial fibrosis, that off-switch fails. The myofibroblasts keep producing collagen, along with other structural proteins like laminin and fibronectin, long after the initial injury has passed.
A signaling molecule called TGF-beta 1 is widely considered the master driver of this process. It pushes normal connective tissue cells to transform into myofibroblasts and ramps up collagen production. In the lungs, the result is that the thin, delicate air sacs (alveoli) where oxygen enters the blood are gradually replaced by thick, stiff scar tissue. In the kidneys and heart, the same process disrupts the organ’s architecture and compromises its function.
Organs Most Commonly Affected
Lungs
Pulmonary interstitial fibrosis is the most recognized form. The scarring replaces the thin walls of the air sacs, making it harder for oxygen to pass into the bloodstream. The most severe version, idiopathic pulmonary fibrosis (IPF), has no identifiable cause and tends to worsen over time. Other forms of interstitial lung disease can result from autoimmune conditions, occupational dust exposure, or medications.
Kidneys
In the kidneys, interstitial fibrosis is paired with a related finding called tubular atrophy, and the two are graded together on biopsy. Fibrosis is considered present when scar tissue exceeds 5% of the kidney’s outer layer (the cortex). This combination is one of the strongest predictors of long-term kidney function decline, regardless of the original kidney disease. It shows up in chronic kidney disease, diabetic kidney damage, and transplant kidneys experiencing chronic rejection.
Heart
In the heart, interstitial fibrosis stiffens the muscle wall between heartbeats. Excess collagen, especially when its fibers become chemically cross-linked, makes the ventricle resistant to filling with blood. This is a key contributor to a type of heart failure where the heart pumps normally but can’t relax properly (sometimes called heart failure with preserved ejection fraction, or HFpEF). Conditions like long-standing high blood pressure, aortic valve disease, and hypertrophic cardiomyopathy all promote this kind of cardiac scarring.
What Causes It
The triggers vary by organ, but several broad categories apply across the board.
- Autoimmune diseases: Conditions like rheumatoid arthritis, scleroderma, and mixed connective tissue disease can drive fibrosis in the lungs and other organs through chronic, misdirected inflammation.
- Environmental and occupational exposures: Long-term inhalation of asbestos fibers, silica dust, mold spores, or bird proteins can trigger lung fibrosis. Silicosis and asbestosis are well-known examples.
- Chronic disease: Diabetes, long-standing hypertension, and repeated kidney injuries can all lead to progressive fibrosis in the affected organ.
- Medications and radiation: Certain chemotherapy drugs and radiation therapy can damage tissue and set off a fibrotic response.
- Smoking and aging: Cigarette smoking and advancing age are independent risk factors, particularly for lung fibrosis. Chronic aspiration of stomach contents and viral infections may also contribute.
- Unknown causes: When no trigger can be identified, the condition is labeled idiopathic. IPF is the most prominent example.
Symptoms and What It Feels Like
Symptoms depend on the organ involved but share a common theme: the organ gradually loses its capacity, so problems tend to creep in slowly rather than arriving all at once.
In the lungs, the earliest symptom is usually breathlessness during physical activity, like climbing stairs or walking uphill. Over time, this progresses to breathlessness at rest. A persistent, dry cough that doesn’t produce mucus is common. Some people notice their fingertips becoming rounded and swollen at the tips, a change called clubbing.
In the kidneys, fibrosis itself rarely causes symptoms you can feel. It typically shows up on biopsy or blood tests as a gradual rise in waste products that the kidneys can no longer clear efficiently. Fatigue, swelling in the legs, and changes in urine output may appear as kidney function declines further.
In the heart, the main symptom is exercise intolerance and shortness of breath, driven by the ventricle’s inability to relax and fill properly. Fluid retention, leg swelling, and fatigue are also common.
How It’s Diagnosed
For lung fibrosis, high-resolution CT scanning (HRCT) is the primary imaging tool. Radiologists look for a specific pattern of findings: a net-like (reticular) pattern concentrated in the lower portions of the lungs near the chest wall, along with honeycombing, which appears as clusters of small, thick-walled cysts typically less than 10 millimeters across. Traction bronchiectasis, where scarring pulls airways open wider than normal, is another hallmark and a strong predictor of how quickly the disease will progress. When all four diagnostic criteria are met on CT, a lung biopsy can often be avoided.
When imaging is inconclusive, a tissue sample may be needed. International guidelines from a 2022 joint statement by four major respiratory societies now recognize a newer, less invasive biopsy technique (cryobiopsy through a bronchoscope) as an acceptable alternative to surgical lung biopsy, provided the center has the right expertise.
In the kidneys, diagnosis requires a needle biopsy. Pathologists assess the percentage of cortical area replaced by scar tissue and the degree of tubular shrinkage. In the heart, cardiac MRI can detect and quantify interstitial fibrosis without a biopsy, measuring the amount of collagen present in the heart wall.
Treatment Options
Current treatments can slow fibrosis but cannot reverse it. For pulmonary fibrosis, two oral antifibrotic medications are approved. A meta-analysis pooling 13 clinical trials found that these drugs significantly reduce the rate of lung function decline, measured by how much air the lungs can hold (forced vital capacity). The effect was consistent whether the fibrosis had a known cause or was idiopathic. Pooled data also showed a significant reduction in mortality for IPF patients, though the evidence was less clear for non-IPF forms of progressive fibrosis.
Beyond medication, pulmonary rehabilitation programs that combine supervised exercise with breathing techniques can meaningfully improve daily function and quality of life. Supplemental oxygen becomes necessary as the disease advances. Lung transplant remains the only option that replaces the damaged tissue entirely, and it’s generally reserved for younger patients with severe, progressive disease.
For kidney fibrosis, treatment focuses on controlling the underlying cause: managing blood pressure, blood sugar, or the autoimmune condition driving the damage. For cardiac fibrosis, treating the root condition (hypertension, valve disease) can slow further collagen accumulation, though existing scar tissue tends to persist.
Prognosis and Long-Term Outlook
Outcomes depend heavily on the organ, the underlying cause, and how early the fibrosis is caught. IPF carries the most sobering prognosis among fibrosing conditions. Data from a large patient registry found that about 34% of IPF patients survived beyond five years after enrollment. The strongest predictors of longer survival were better baseline lung function, particularly the lungs’ ability to transfer oxygen into the blood, along with whether the patient needed supplemental oxygen at the time of diagnosis.
For kidney fibrosis, the percentage of scarred tissue on biopsy correlates directly with future kidney function. Mild fibrosis caught early, with aggressive management of the underlying disease, can remain stable for years. Severe fibrosis generally progresses toward kidney failure.
Cardiac interstitial fibrosis tends to worsen as the underlying heart condition progresses, but the rate varies. Fibrosis detected early by cardiac MRI in someone with well-controlled blood pressure, for example, may remain clinically insignificant for a long time.
Can It Be Reversed?
As of now, established interstitial fibrosis is considered irreversible. Current antifibrotic drugs slow the pace of scarring but do not halt or undo it. This is one of the most active areas of medical research. Stem cell therapies that could potentially repair damaged tissue are being studied, as are tiny biological particles called exosomes that carry molecular instructions capable of dialing down the fibrotic process. Combination drug regimens and newer classes of medications targeting the specific molecular pathways that activate myofibroblasts are also in clinical trials. None of these approaches has yet reached routine clinical use, but several have shown encouraging results in early-phase studies.